Pramlintide is an injectable synthetic analogue of amylin, a hormone the pancreas releases alongside insulin, sold as Symlin and FDA-approved since 2005 as an add-on therapy for insulin-treated type 1 and type 2 diabetes. It is taken before meals, in addition to (not instead of) mealtime insulin, and its own label carries a boxed warning for severe hypoglycemia when combined with insulin. It predates the modern GLP-1 weight-loss drug class by nearly two decades and works through a different hormone system, though its appetite-suppressing and modest weight-loss effects have drawn renewed interest as amylin-based drugs like cagrilintide are developed for weight management.
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Amylin analogue |
| Primary research interest | Adjunctive mealtime glycemic control in insulin-treated diabetes |
| Highest available evidence | Tier 1 – FDA-approved via randomized, placebo-controlled trials |
| Human research available | Yes – established since 2005 approval |
| Development status | Approved (Symlin, 2005); developed by Amylin Pharmaceuticals, now AstraZeneca |
| Regulatory status | FDA-approved as adjunctive therapy to mealtime insulin; not approved as a standalone weight-loss drug |
| Last reviewed | 2026 |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Pramlintide |
| Alternative names | Symlin (brand), AC137 (code name), pramlintide acetate |
| Peptide sequence | 37 amino acid analogue of human amylin (islet amyloid polypeptide), with proline substitutions at positions 25, 28, and 29 to reduce aggregation |
| Amino-acid length | 37 residues |
| Molecular formula | C171H267N51O53S2 (free peptide) |
| Molecular weight | ~3949.5 g/mol (free peptide, derived from formula); the acetate salt hydrate form is listed at 4027.49 g/mol |
| CAS Registry Number | 151126-32-8 |
| PubChem CID | 70691388 |
| Chemical modifications | Pro25, Pro28, Pro29 substitutions relative to native human amylin, reducing aggregation tendency |
| Peptide class | Amylin receptor agonist |
| Primary biological target | Amylin receptor |
| Developer or originator | Amylin Pharmaceuticals (rights now with AstraZeneca) |
| Development status | FDA-approved since March 2005 |
What it is
Pramlintide is a 37 amino acid synthetic peptide based on human amylin, with proline substitutions at three positions engineered to resist the self-aggregation that makes native human amylin difficult to manufacture as a stable drug. Amylin Pharmaceuticals developed it (the company was later acquired, and rights now sit with AstraZeneca). The FDA approved it in March 2005, sold as Symlin, as adjunctive therapy for people with type 1 or type 2 diabetes who use mealtime insulin and have not achieved adequate control despite optimal insulin therapy. It is not a substitute for insulin and must be used alongside it.
How does it work?
Plain-English explanation
Amylin is a hormone the pancreas normally releases together with insulin after eating. In people with diabetes who inject insulin, this second hormone is largely missing. Pramlintide replaces that missing signal: it slows how fast the stomach empties, reduces appetite, and tells the liver to stop releasing extra sugar right after a meal, all of which help smooth out the blood sugar spike that follows eating.
Technical explanation
Pramlintide activates amylin receptors, which are distinct from but related to calcitonin receptors, working alongside GLP-1 and insulin in the coordinated hormonal response to eating. It suppresses postprandial glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system pathways, distinct from and complementary to the GLP-1 receptor mechanism used by liraglutide, semaglutide, and tirzepatide. Its half-life is short (about 48 minutes), which is why it is dosed before each major meal rather than once daily or once weekly like GLP-1 drugs.
Potential benefits and research applications
Glycemic control in insulin-treated diabetes
What is being investigated: additional HbA1c improvement when added to mealtime insulin in type 1 and type 2 diabetes. How the effect might occur: replacement of the missing postprandial amylin signal, reducing after-meal glucagon and glucose spikes. Evidence: FDA-reviewed 6-month trials showed placebo-subtracted HbA1c improvements of about 0.25 to 0.34 percentage points in both type 1 and type 2 diabetes. Strength: has been shown in randomized, placebo-controlled trials supporting FDA approval. Limitation: the HbA1c improvements are modest in absolute terms compared with entire drug classes developed since, and the drug requires an additional injection before every major meal, a considerable treatment burden.
Modest weight reduction as an add-on to insulin
What is being investigated: weight change in people using pramlintide alongside insulin, since insulin therapy alone commonly causes weight gain. How the effect might occur: appetite suppression and slowed gastric emptying. Evidence: FDA-reviewed trials found pramlintide-treated participants lost 0.8 to 1.6 kg over 6 months while placebo groups gained weight or stayed roughly stable. Strength: has been shown in randomized, placebo-controlled trials in the approved population. Limitation: the amounts involved are small (roughly 1 to 3 pounds) compared with the double-digit percentage weight loss seen with dedicated weight-loss drugs like semaglutide or tirzepatide, and pramlintide is not FDA-approved as a weight-loss drug in its own right.
Historical and mechanistic basis for newer amylin-based weight-loss drugs
What is being investigated: whether amylin receptor activation, refined and dosed differently than pramlintide, can produce meaningful weight loss on its own or combined with GLP-1 drugs. How the effect might occur: the same appetite and gastric-emptying pathways pramlintide established clinically, extended with longer-acting molecules. Evidence: pramlintide’s approval and mechanism directly informed the development of longer-acting amylin analogues such as cagrilintide, now being studied and in one case (as CagriSema) combined with semaglutide for weight loss. Strength: pramlintide itself is the original, FDA-approved proof that amylin receptor activation is druggable and has real metabolic effects in humans. Limitation: pramlintide’s own short half-life and need for injection before every meal make it impractical as a modern weight-loss drug on its own, which is precisely why longer-acting successors were developed.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Pramlintide is FDA-approved and dispensed by prescription under the brand name Symlin, so its dosing is published in FDA-approved labeling.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Type 1 diabetes (approved) | Subcutaneous | Starting 15 mcg, titrated in 15 mcg increments to a 30 or 60 mcg maintenance dose | Before each major meal | Ongoing/chronic | FDA-approved prescribing information |
| Type 2 diabetes (approved) | Subcutaneous | Starting 60 mcg, increased to 120 mcg after tolerance | Before each major meal | Ongoing/chronic | FDA-approved prescribing information |
Mealtime insulin doses are typically reduced by about 50% when pramlintide is started, to reduce the risk of severe hypoglycemia (boxed warning).
Amounts studied in human research
For type 1 diabetes, the approved regimen starts at 15 mcg by subcutaneous injection immediately before major meals, increasing in 15 mcg increments at least 3 days apart as tolerated, up to a maintenance dose of 30 or 60 mcg per dose. For type 2 diabetes, the approved regimen starts at 60 mcg before major meals, increasing to 120 mcg after at least 3 days without clinically significant nausea. In both cases, mealtime insulin doses are typically reduced by about 50 percent when pramlintide is started, to reduce the risk of severe hypoglycemia.
Practitioner and community-reported protocols
Not consistently reported. As an older, FDA-approved drug requiring careful insulin co-management and a boxed warning for severe hypoglycemia, pramlintide has not developed an informal or research-chemical dosing culture separate from its approved, medically supervised regimen.
What circulates E5
Not consistently reported. As an older, FDA-approved drug requiring careful insulin co-management and a boxed warning for severe hypoglycemia, pramlintide has not developed an informal or research-chemical dosing culture separate from its approved, medically supervised regimen.
Its dosing comes from the FDA-approved Symlin label rather than circulating figures: 15 mcg before meals titrated up to 30 or 60 mcg (type 1 diabetes), or 60 mcg before meals titrated up to 120 mcg (type 2 diabetes), in both cases alongside a reduced mealtime insulin dose.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Pramlintide carries an FDA boxed warning: when used with insulin, it increases the risk of severe hypoglycemia, particularly in type 1 diabetes, with severe events typically occurring within 3 hours of an injection. This is why insulin doses are reduced by about half when starting pramlintide, and why careful patient selection and instruction are required. The most common non-hypoglycemia side effect is nausea, especially during dose titration, which is why the type 2 diabetes regimen increases the dose only after nausea has resolved at the current dose. It must never be mixed in the same syringe as insulin and is injected separately.
Regulatory and developmental status
Pramlintide has been FDA-approved since March 2005, sold as Symlin, as adjunctive mealtime therapy for adults with type 1 or type 2 diabetes using insulin who have not achieved adequate glucose control. It is not approved as a standalone weight-loss drug. It remains marketed, though it has been overshadowed commercially by the GLP-1 drug class developed in the years since its approval.
Frequently asked questions
What is pramlintide?
An injectable, synthetic analogue of amylin, a pancreatic hormone, sold as Symlin and FDA-approved as an add-on to mealtime insulin for type 1 and type 2 diabetes.
How does it work?
It replaces the amylin signal that is largely missing in people who inject insulin, slowing stomach emptying, reducing appetite, and suppressing the glucagon spike that follows a meal.
What dosage has been studied?
For type 1 diabetes: 15 mcg before meals, titrated up to 30 or 60 mcg. For type 2 diabetes: 60 mcg before meals, titrated up to 120 mcg. Both are injected immediately before major meals, alongside a reduced dose of mealtime insulin.
Does it cause weight loss?
A modest amount. FDA-reviewed trials showed about 0.8 to 1.6 kg of weight loss over 6 months, small compared with dedicated weight-loss drugs, and it is not FDA-approved as a weight-loss treatment on its own.
Is it approved?
Yes, since March 2005, for insulin-treated type 1 and type 2 diabetes, sold as Symlin.
What is the boxed warning about?
Severe hypoglycemia when pramlintide is combined with insulin, particularly in type 1 diabetes, with severe episodes typically occurring within 3 hours of an injection. Insulin doses are reduced by about half when starting pramlintide to manage this risk.
How is it different from semaglutide or liraglutide?
It targets amylin receptors rather than GLP-1 receptors, is dosed before every meal rather than daily or weekly, must be used alongside insulin rather than as a standalone treatment, and produces much smaller weight loss than the GLP-1 drug class.
What remains unknown?
How amylin-pathway drugs perform when engineered for longer action and dosed specifically for weight loss is an active area of research (see cagrilintide), separate from pramlintide’s own established, narrower role as a mealtime diabetes add-on.
Bottom line
Pramlintide is a well-established, FDA-approved amylin analogue that has been used since 2005 as an add-on to mealtime insulin in diabetes, with modest but real HbA1c and weight benefits documented in its approval trials. It carries a boxed warning for severe hypoglycemia when combined with insulin and requires an injection before every major meal, a burden that has limited its use as newer, longer-acting drugs have emerged. Its historical importance is as the clinical proof that amylin receptor activation is a real, druggable pathway, one that longer-acting successor molecules like cagrilintide are now trying to exploit for meaningful weight loss rather than the small effect pramlintide itself produces.